Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute oral bioavailability and pharmacokinetics study of seltorexant in healthy adults
NL-OMON51594Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of seltorexant in major depressive disorder (MDD) and Insomnia, sponsored by Janssen Pharmaceutical. Primary endpoint: Absolute bioavailability of seltorexant. Started Feb 2022; status: completed.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on NL-OMON51594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51594.